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ABSTRACT 
Alzheimer’s disease (AD), despite over a century of research, does not have a 
clearly defined pathogenesis for the sporadic form that makes up the majority of disease 
incidence. A variety of correlative risk factors have been identified, including the three 
isoforms of apolipoprotein E (ApoE), a cholesterol transport protein in the central 
nervous system. ApoE ε3 is the wild-type variant with no effect on risk. ApoE ε2, the 
protective and most rare variant, reduces risk of developing AD by 40%.  ApoE ε4, the 
risk variant, increases risk by 3.2-fold and 14.9-fold for heterozygous and homozygous 
representation respectively. Study of these isoforms has been historically complex, but 
the advent of human induced pluripotent stem cells (hiPSC) provides the means for 
highly controlled, longitudinal in vitro study. The effect of ApoE variants can be further 
elucidated using this platform by generating isogenic hiPSC lines through precise genetic 
modification, the objective of this research. As the difference between alleles is 
determined by two cytosine-thymine polymorphisms, a specialized CRISPR/Cas9 system 
for direct base conversion was able to be successfully employed. The base conversion 
method for transitioning from the ε3 to ε2 allele was first verified using the HEK293 cell 
line as a model with delivery via electroporation. Following this verification, the 
transfection method was optimized using two hiPSC lines derived from ε4/ε4 patients, 
with a lipofection technique ultimately resulting in successful base conversion at the 
same site verified in the HEK293 model. Additional research performed included 
characterization of the pre-modification genotype with respect to likely off-target sites 
and methods of isolating clonal variants.   
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1. INTRODUCTION 
1.1. Overview 
Alzheimer’s disease is a complicated, costly disease that scientific research has been 
attempting to understand for over a hundred years. In that time period, though the cause 
of sporadic Alzheimer’s disease was not defined, a multitude of risk factors have been 
identified. The most impactful genetic risk factor was determined to be the three 
isoforms of Apolipoprotein E, a cholesterol transport protein in the central nervous 
system. Though the variants of ApoE have a dramatic effect on an individual’s risk of 
developing Alzheimer’s disease, the causal relationship is unknown. This lack of clarity is 
exacerbated by the interactions of other risk factors and the limitations of study models 
available. One solution that would isolate ApoE variants from any other risk factor is to 
use induced pluripotent stem cells. These cells can be genetically modified in vitro from 
one genotype to another, and then differentiated into the very neural cell types affected 
by Alzheimer’s disease. Generation of such isogenic pluripotent cell lines would provide a 
well-characterized, easily controlled model for use in longitudinal study of the 
pathogenesis of Alzheimer’s disease. 
1.2. Organization 
Chapter 2 discusses the current understanding of Alzheimer’s disease, including the 
specific genetic risk factor APOE. Advances in genetic modification techniques are also 
discussed. Chapter 3 discusses the methodology employed to transfect cells in culture, 
assess genetic modification, and optimize the clonal line generation procedure. Chapter 
4 describes the results generated by these methods. Chapter 5 summarizes the key 
accomplishments and suggests future work. 
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2. LITERATURE REVIEW 
2.1. Alzheimer’s Disease Characterization 
 Alzheimer’s disease is a household name as the foremost cause of dementia. This 
complex neurodegenerative disorder places a massive burden on society in its economic 
and quality of life impact. More than ten percent of the population aged 65 and older has 
Alzheimer’s disease. Based on the current incidence, a new patient develops Alzheimer’s 
disease every 66 seconds, a rate that will only increase as the population ages. [1] This 
prevalence has a cost. Per “Changing the Trajectory of Alzheimer's Disease”, a report 
issued by the Alzheimer’s Association, costs associated with patient care alone are 
projected to rise to more than $1.1 trillion by 2050 if disease prevalence remains 
unchecked. [2] NIH funding allocated for supporting research rose to $910 million in 
2016 from $503 million in 2012. This figure only includes the federal contribution to 
research funding, with additional costs incurred by the private sector, particularly when 
clinical trials are involved. [3] At the individual level, the patient is not the only victim of 
their cognitive decline. Caregivers are severely impacted by the progression of the 
disease. Over a third of Alzheimer’s patients’ caregivers are over the age of 65 and 
susceptible to their own difficulties that come with age. Over 15 million people acted as 
caregivers in 2016, exhausting time, money, and their own quality of life in aiding 
dementia patients. [1] Perhaps the greatest burden of Alzheimer’s disease is that it has 
no cure. In 2014, Alzheimer’s disease was reported as the sixth leading cause of death in 
the United States, and the only leading pathology-related cause to have an increased 
death rate from 2004 to 2014. Age-adjusted death rates declined during this period for 
all other non-injury causes, including heart disease, cancer, and stroke. [4]  
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 Alzheimer’s disease has been studied for more than a century without achieving 
an absolute understanding of the cause or development. The late-stage physical 
pathology has been well-documented, featuring intra- and extracellular proteinaceous 
aggregations and loss of functioning neurons in correlation with cognitive decline. The 
amyloid cascade hypothesis has been the leading causal suggestion for years, positing 
that the neurodegenerative pathway begins with the accumulation of extracellular 
plaques of the amyloid-β peptide. [5] While the normal function of this peptide has not 
been well understood, the pathologic aggregation has been the subject of intense study. 
This aggregation is dependent on the cleavage mechanisms that process the amyloid 
precursor protein (APP). In both pathways, the transmembrane APP is cleaved initially 
to form a membrane-bound fragment and a secreted fragment. The membrane-bound 
fragment is again cleaved by γ-secretase to separate the intracellular and extracellular 
domains. In the non-amyloidogenic pathway, the first cleavage via α-secretase results in 
a long initial secreted fragment, APPsα, and so leaves a short extracellular domain, 
Aβ40, to be released by the γ-secretase activity. In the amyloidogenic pathway, the first 
cleavage via β-secretase takes place closer to the N-terminus of APP, resulting in a 
shorter secreted fragment than APPsα and leaving a longer extracellular domain for later 
release as Aβ42. This alternate amyloid-β protein is more prone to aggregation, and as 
such is indicated as a key component in the pathogenesis of Alzheimer’s disease. A 
variety of options have been suggested as to the form of amyloid-β that prompts the 
neurogenerative cascade, ranging from the originally-indicated senile plaques to soluble 
oligomers. [6] One specialized amyloid-β hypothesis suggests that amyloid-β oligomers 
form neurotoxic calcium ion channels in neurons, leading to cell death and the clinical 
neurodegenerative effects. [7] Other research complementary to that naming amyloid-β 
as the key component has demonstrated a positive correlation between synaptic health 
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and plasticity and secretion of APPsα in animal models. [8] However, the amyloid-β 
hypotheses have complications. Another common hypothesis as to the casual pathway of 
Alzheimer’s disease features tau phosphorylation and aggregation.  
 While the pathology described above is characteristic of all cases of Alzheimer’s 
disease, the disorder can be parsed into groups based on the age and heritability of 
development. Familial Alzheimer’s disease (FAD) is characterized by inheritable 
mutations in APP, presenilin 1, or presenilin 2. These mutations predispose the APP 
pathway to production of Aβ42 and the resulting accumulation of amyloid-β plaques. 
FAD is typically early on-set, with patients commonly presenting symptoms in their 40s 
to early 60s. FAD is also relatively rare, accounting for less than 5% of all Alzheimer’s 
disease cases. Sporadic Alzheimer’s disease (SAD) comprises the remainder of 
Alzheimer’s disease cases, and in contrast with FAD, does not correlate with any 
inheritable, deterministic genetic mutations. SAD is typically late on-set, presenting in 
patients older than 65. Given the lack of deterministic mutations, improved 
understanding and potential treatment of SAD requires characterization of the causal 
pathway that precipitates the known pathology.  
2.2. Apolipoprotein E, a Genetic Risk Factor 
In the effort to better characterize SAD and its cause, a variety of technologies 
converged to implicate Apolipoprotein E (APOE) as the single most correlative genetic 
risk factor. The early 1990s featured two parallel efforts at the Duke Alzheimer’s Disease 
Research Center, one exploring genome-wide association studies (GWAS) to find 
correlative gene networks, and one studying the pathology of Alzheimer’s disease, 
specifically amyloid-β plaques, to investigate protein function. The results of the former 
suggested a strong relationship between development of Alzheimer’s disease and gene 
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expression from chromosome 19. [9] The results of the latter indicated that a protein 
matching the conserved regions of ApoE was present in amyloid-β plaques. After the 
connection was made between Alzheimer’s disease and chromosome 19, and 
chromosome 19 and ApoE, more specific GWAS results strongly indicated a correlation 
between isoforms of ApoE and the prevalence of SAD.  
 ApoE is involved in a variety of pathways in the central nervous system, but has a 
primary role of cholesterol transport. Produced almost exclusively by astrocytes, the 
protein is comprised of a helical bundle at the N-terminus and a longer, hinged single 
helix at the C-terminus. (Figure 1) These two segments of ApoE are distinguished by 
their function, with the N-terminus binding to transported lipoproteins and the C-
terminus interacting with receptor proteins. [10] There are three common variants of 
APOE; ε2, the protective allele; ε3, the wild-type allele, and ε4, the risk allele. ApoE ε3 is 
the most common allele in the general population, followed by ε4 and ε2. These variants 
are distinguished by two single-nucleotide polymorphisms (SNPs) at the 112 and 158 
amino acid positions. (Table 1) The corresponding protein isoforms appear to differ in 
the interaction between the lipid-binding domain and the N-terminus. When an arginine 
residue is present at the 112 position as in the ε4 variant, the secondary structure allows 
for a salt bridge to form between the arginine residue at the 61 position and the 
glutamine residue at the 255 position on the lipid-binding domain. When a cysteine is 
present in this position as in the ε3 and ε2 variants, the secondary structure does not 
permit such a salt bridge. [11] The variation in structure between the isoforms is 
implicated as the cause of the variable pathogenic risk. The most common explanation 
for the variable risk was a suggestion that the ApoE isoforms have disparate capabilities 
of binding Aβ fragments for clearance, with ε4 being the least capable and thus allowing 
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for the extracellular aggregation of senile plaques. [12] However, a more recent 
hypothesis proposes that ApoE and Aβ are competing substrates in their interaction with 
cellular clearance pathway receptors, specifically low-density lipoprotein receptor-
related protein 1 (LRP1) and LDL receptor (LDLR). [13] Whatever the causal 
relationship, it is clear that ApoE isoforms are involved in complex pathways.  
Allele Polymorphisms 
General 
Population 
Frequency 
AD 
Population 
Frequency 
Effect on Risk 
ε4 Arg112; Arg158 13.7% 36.7% 
3.2-fold more 
likely (one 
allele); 14.9-fold 
more likely (two 
alleles) 
ε3 Cys112; Arg158 77.9% 59.4% 
Average (wild-
type) 
ε2 Cys112; Cys158 8.4% 3.9% 40% less likely 
Table 1. Comparison of the three major alleles of APOE with respect to their prevalence 
and effect on the risk of developing Alzheimer’s disease. [14] 
 Other environmental and lifestyle factors have been identified as affecting an 
individual’s risk for developing Alzheimer’s disease. Age is the most dramatic correlative 
factor, with prevalence of Alzheimer’s disease increasing in older demographics. One risk 
factor study found that patient risk of developing Alzheimer’s increases by an average of 
1.5-1.8-fold in successive age groups spanning five years from age 60 to age 95. [15] 
Health factors have been of additional interest. Vascular risk factors in particular have 
been found to correlate with the prevalence of Alzheimer’s disease, including midlife 
hypertension, diabetes, high cholesterol, and lifestyle risks, such as obesity and smoking. 
[16] Other neurological conditions have been shown to share a correlation with 
development of Alzheimer’s disease as well, including post-traumatic stress disorder 
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(PTSD) and head injury. In a study of the aging veteran population, it was found that 
those who suffered from PTSD had a higher incidence of Alzheimer’s disease of 1.77-
2.31-fold relative to veterans without PTSD. [17] A meta-analysis of 32 studies 
investigating the link between head injury and the development of Alzheimer’s disease 
later in life found an overall increased risk of 1.51-fold with respect to patients that did 
not experience head injury. [18] Beyond health factors, education levels have been 
indicated as a potential risk factor for developing AD. A compilation of international risk 
factor studies suggested that a lower education corresponds with a doubled risk of 
developing Alzheimer’s disease. [19] Possible explanation for the impact of education 
suggests that an increased “cognitive reserve” provides additional synapses that can be 
used to maintain homeostasis when neurodegeneration occurs. [20] This great diversity 
of risk factors and their potential interactions emphasizes the difficulty in elucidating the 
effect of APOE without accounting for these factors.  
2.3. Methods of Studying ApoE Isoforms 
Researching neurological disorders presents many challenges, with one of the 
greatest being determining appropriate modeling methods. This is critical for 
comparison of the three isoforms of APOE, requiring a tightly controlled, longitudinal, 
and human-transferable model. The approach closest to the ground truth is analysis of 
primary human tissue, capturing the complexity of the pathology in question exactly as it 
presents in the nervous system with all known and unknown factors at work. 
Unfortunately, primary tissue in the central nervous system is typically available for 
harvest at time of death, and as such does not typically provide insight into the early 
stages, developmental pathway of disease, or effects of treatment. Reliance on primary 
human tissue also precludes explicit control of common risk factors, preventing study of 
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truly isolated variables as is needed to characterize the impact of APOE variants. Use of 
animal models rectifies some of these issues, allowing for more direct control and the 
ability to perform analyses over time. A variety of mouse models have already 
contributed to greater understanding of Alzheimer’s disease. The positive correlation 
between the presence of Aβ42 and the formation of the amyloid-β plaques, increased 
plaque formation with subject age, and the potential neurotoxicity of soluble amyloid-β 
oligomers were all identified and confirmed in various transgenic mouse models. [21] 
One drawback of animal models is the inability to model SAD. Since the root cause of 
SAD is still under investigation, generation of animal lines that express the Alzheimer’s 
disease phenotype relies on overexpression of FAD mutations. [22] Even more 
specialized animal models are required to generate neurofibrillary tangles as that 
pathology is typically not seen in models that only rely on overexpression of Aβ42. [23] 
While such direct approaches are useful when analyzing downstream effects of the 
pathology of Alzheimer’s disease, they do not allow for study of the natural cause as 
artificial causes are induced. Other cause for concern with animal models is the lack of 
translation of successful therapies from animal to human trials. This gap between the 
two systems indicates an incomplete approximation of the disease using the current 
modeling approaches. [24] Such a gap adds potential error to an already complex 
pathway.  
The third approach available for studying the effect of APOE is the use of cultured 
human cells, specifically stem cells. Human pluripotent stem cells can be used for 
modeling tissues in a dish that are otherwise difficult to acquire. Previously, such cells 
could be obtained as embryonic stem cells from blastocysts generated through in vitro 
fertilization. This method met with scrutiny due to the limited cell numbers achieved and 
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the ethical dilemma posed by their source. In 2006, it was reported that terminally 
differentiated cells could be “reprogrammed” to a pluripotent state by exposing the cells 
to certain transcription factors (Oct4, Sox2, Klf4 and c-Myc). [25] Other methods have 
since been developed to both increase efficiency and reduce the lasting footprint of the 
conversion method. [26] Delivery of these four vectors via the Sendai virus has proven to 
be a robust solution as these recombinant vectors are not integrated into the host 
genome. Reprogramming with the Sendai virus is also reported with higher efficiency 
than other viral techniques. [27] Using such methods, human induced pluripotent stem 
cells (hiPSCs) can be generated from any living individual, retaining the genotype of the 
patient with the added abilities to self-renew in culture and to be differentiated into any 
desired cell type. Hypothetically, these cells would also express pathological phenotypes 
when differentiated into the tissues that are diseased in the patient. A variety of studies 
have demonstrated this modeling to be possible, from imitation of action potential 
changes expressed in cardiomyocytes derived from hiPSCs from patients with a mutation 
associated with cardiac arrhythmia, to recapitulation of defective neuronal 
differentiation and migration in hiPSCs from patients with familial dysautonomia. [28], 
[29] Familial Alzheimer’s has also been successfully modeled using patient-derived 
hiPSCs with respect to generation of both amyloid-β aggregation and neurofibrillary 
tangles of hyperphosphorylated tau given known mutation of APP. [30] This method 
provides a platform for rigorous control of environmental factors, grants ease of access 
for analysis and longitudinal study, and removes the complications of using another 
species as the model basis. Given these hiPSCs as intrinsically clonal populations, there 
is the opportunity to use gene modification methods at the cellular level to create 
parallel, isogenic cell lines to isolate the APOE variant as the only distinguishing 
characteristic.  
 10 
 
2.4. Genetic Modification Methods 
 Gene modification methods have evolved rapidly in recent history. The use of 
meganucleases, engineered versions of restriction enzymes, was one of the first 
adaptations of native DNA modification machinery for engineering purposes. Each 
meganuclease targets a large, typically unique recognition site in the genome and effects 
a double-stranded break (DSB) in the genome at the recognition site. Zinc finger 
nucleases (ZFNs) are combinations of protein monomers that each match three 
nucelotides. The combined targeting proteins can be conjugated to the FokI nuclease to 
create the same DSB described previously, activating endogenous repair pathways. ZFNs 
are limited in size by the heterogenous structure of the targeting proteins that limits the 
Transcription activator-like effector nucleases (TALENs) are similar to ZFNs in that they 
are comprised of ordered recognition protein domains and require conjugation to an 
endonuclease to effect the DSB, but have an advantage in that each targeting monomer 
only targets a single base. This allows for more precise design of targeting mechanisms; 
however, the conserved nature of the targeting monomers can complicate viral 
transduction methods of vector delivery. Both ZFNs and TALENs, while programmable, 
are time-consuming and expensive to manufacture given that each targeted sequence 
must be translated into the targeting mechanism in a specific, compatible sequence of 
monomers. The revolution in programmable targeting arrived in the form of Clustered 
regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) 
proteins. These systems relied on DNA targeting through specific guide RNA strands and 
the resulting Waston-Crick base-pairing rather than a combination of protein 
monomers. This simplification of the targeting mechanism reduced the time and cost 
involved with design for a new target and made genetic modification more accessible. 
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 Though the evolution of genetic modification methods has advanced rapidly with 
respect to the ease and specificity of the targeting mechanism, all four of the methods 
previously discussed create a DSB in the targeted DNA sequence and rely on the same 
repair mechanisms to silence or alter the gene. If the endogenous repair machinery 
solves the damaged DNA without additional intervention, the two strands are religated 
through a process called non-homologous end joining (NHEJ). In NHEJ, the native 
machinery attempts to join the broken strands by adding or removing nucleotides based 
on any overhangs present. These insertions and deletions, or indels, are useful in 
silencing genes by altering the sequence or even causing a frameshift mutation. The next 
step in modification techniques provided a method to not just silence genes, but to alter 
the sequence. In homology-directed repair, long homology arms are supplied that span 
the native genome sequence across the DSB, but with a desired mutation in between the 
matching sequences. The native machinery then uses these homology arms as a template 
for filling the gap rather than completing the break with random nucleotides, inserting 
the mutation into the repaired DNA. HDR has since been validated many times over as a 
method for supplying an altered sequence for the targeted gene, but the method still has 
many drawbacks. These include a high prevalence of off-target effects, low modification 
efficiency, and the additional work required to generate and deliver the homology arms. 
 In order to improve upon the efficiency and specificity of CRISPR/Cas9, a variety 
of techniques have been developed. One of these techniques, published by the David Liu 
lab at Harvard University, is centered around direct base conversion of the targeted 
nucleotide. [31] This improved base editor includes multiple functional groups added to 
a catalytically inactivated Cas9 protein. The first of these is the cytidine deaminase that 
converts the cytosine nucleotide to uracil. The second additional functional group, uracil 
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DNA glycosylase inhibitor, prevents the native base excision repair machinery from 
removing the RNA base and replacing it with the original cytosine. The third 
modification was restoration of activity to the HNH endonuclease domain which creates 
a single-stranded break in the off-target strand that, at this point, is still guanine. The 
damage prompts other endogenous repair machinery to remove the guanine through 
mismatch repair and replace it with adenine. Other machinery eventually replaces the 
uracil with thymine, completing the transition from cytosine to thymine without ever 
creating a DSB or relying on the low efficiency of HDR. The efficiency of this method is 
reported as 15-75% with less than 1% indel formation, compared to 0.5% conversion 
efficiency and 4.3% indel formation when standard CRISPR/Cas9 and HDR are used to 
create the mutation. Such precision in correcting point mutations brands this specialized 
base editor as an ideal tool for use in the generation of these isogenic cell lines. 
3. METHODS 
3.1. Verification in HEK293 Cell Line 
 Determination of the gene modification system included identification of the 
vectors, delivery method, and platform for verification. The human embryonic kidney 
cell line HEK293 was chosen as the verification model for the base modification system. 
This line is reliably cultured in vitro and was the platform used to demonstrate the 
efficacy of the modified CRISPR/Cas9, providing an opportunity to replicate the 
published results prior to attempting the direct base conversion in hiPSCs. Use of this 
model also allowed for optimization of delivery method parameters for cell survival and 
gene modification.  
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CRISPR/Cas9 systems have been successfully delivered in a variety of methods 
since their discovery. This research posed additional constraints that limited the delivery 
options available for use. Given that the intent of generating these isogenic pluripotent 
cell lines is to minimize the genetic footprint of the modification, stable integration of the 
Cas9 vector into the native genome was distinctly undesirable. This precluded use of 
common viral vectors as most function by inserting the transduced cassette into the host 
genome, altering the genotype of the cell line and potentially interrupting other vectors. 
Such permanent expression of the Cas9 protein could also exacerbate off-target effects as 
the protein would continue to be expressed. Lentiviral and adeno-associated viral vectors 
were among those rejected in favor of transient expression. [32] Another consideration 
for the gene delivery method was the low yield process of clonal line generation in 
principal. With the known poor survival of single cell isolation, it was vital that the 
method chosen did not add additional cytotoxic burden and further decrease the chances 
of expansion of modified cells. In the interest of maintaining consistency with the 
published method and the described constraints, electroporation was chosen as the 
method of transient transfection. 
Three separate plasmids were used to deliver the required components. The 
modified Cas9 vector, pCMV-BE3, was a gift from David Liu (Addgene plasmid # 73021). 
The targeting sequences for the modification sites were cloned separately into the 
backbone pFYF1320, a gift from Keith Joung (Addgene plasmid # 47511). The base 
editor and guide RNA plasmids were delivered at a mass ratio of 3:1 in favor of the base 
editor in all experiments. The plasmid containing the fluorescent reporter GFP, pEF-
GFP, was a gift from Connie Cepko (Addgene plasmid # 11154). This plasmid was 
delivered at as low a concentration as possible in order to increase the likelihood that 
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positive GFP expression was correlated with transfection and expression of the other two 
plasmids. 
The evaluation methods for the HEK293 verification were used as the basis for all 
evaluation. Verification of survival and transfection was first assessed qualitatively via 
fluorescent microscopy. Each sample was photographed at twenty-four hour intervals 
following electroporation up to seventy-two hours using brightfield and fluorescent 
channels (EVOS® FL). Brightfield imaging indicated the relative viability of the cells 
post-transfection. Positive GFP expression in the fluorescent channel was used as 
indication of successful transfection. At seventy-two hours post-transfection, this relative 
viability and GFP expression were quantified using flow cytometry. Genetic modification 
was assessed through sequencing. Sanger sequencing was performed on PCR products 
generated from bulk samples. Sanger sequencing and next-generation Illumina 
sequencing were also performed on PCR products from samples enriched for GFP 
positive cells through fluorescence-activated cell sorting (FACS). The next-generation 
sequencing method provided quantification of the modification efficiency. 
The first HEK293 verification experiment employed increasing plasmid 
concentrations to determine the concentration required to effect the desired mutation at 
a detectable scale. HEK293 cells were harvested from 10cm culture plates at ~80% 
confluency using Accutase. The cells were pelleted and washed with phosphate-buffered 
saline (PBS), then pelleted and resuspended in Neon® Resuspension buffer at 
approximately 5*106 cells per aliquot. The three-plasmid system was added to each 
aliquot in a gradation of plasmid concentration from 0.12μg/1*106cells to 
1.6μg/1*106cells with a constant concentration of 20ng/1*106cells of pEF-GFP and a 3:1 
ratio of pCMV-BE3:APOE- pFYF1320. Each sample was then electroporated using a 
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100μL Neon® Tip with settings of 1100V pulse amplitude, 20ms pulse length, and 2 
pulses. (Neon® Transfection System). Samples were immediately deposited drop-wise 
into a 10cm culture plate containing antibiotic-free media, DMEM + 10% FBS, and 5μM 
Rho kinase inhibitor, and returned to the incubator. Microscopy images were recorded 
every twenty-four hours followed by harvest and flow cytometry analysis after seventy-
two hours total. Genomic DNA (gDNA) was extracted from the harvested cells. 
(QIAGEN® DNeasy® Blood & Tissue Kits) PCR amplification of the APOE gene was 
performed using the Phusion® High-Fidelity PCR Kit. The resulting PCR products from 
the heterogeneous population were submitted for Sanger sequencing to assess 
modification on a bulk scale. 
Following this coarse assessment of modification, the transfection procedure 
described above was repeated with a set plasmid concentration of 1.6μg/1*106cells. At 
seventy-two hours post-transfection, the transfected cells were sorted via FACS based on 
GFP expression. gDNA was harvested from the GFP positive, GFP negative, and unsorted 
populations, followed by PCR amplification of the APOE gene. These resulting PCR 
products were submitted for both Sanger sequencing and next-generation sequencing.   
3.2. Translation to hiPSCs 
The generation of the hiPSC lines from patients was performed by a third party. 
Peripheral blood mononuclear cells (PBMCs) were harvested and redirected to 
pluripotency by exposure to the KMOS transcription factors, KLF4, c-MYC, OCT4, and 
SOX2, transiently expressed by Sendei virus transduction. Two lines of interest were 
used specifically in this project, one from an Alzheimer’s disease patient, iPS-160, and 
one from a non-demented control patient, iPS-384. The genotyping for each line was 
performed using Sanger sequencing for both the PBMCs and the reprogrammed hiPSCs.  
 16 
 
The iPS-160 and iPS-384 cell lines were used to transition from the model 
HEK293 cell line to the patient-derived hiPSCs. Simple carryover of the electroporation 
technique used to transfect the HEK293 cell line revealed that more optimization was 
required to yield living, transfected cells. The electroporation settings were revisited in a 
multi-parameter assessment of cell survival and GFP expression with respect to changes 
in voltage, pulse length, and pulse number. Voltage was either 1100V and 1200V, pulse 
length was 10ms, 20ms, or 30ms, and pulse number was either 1 or 2 pulses. All samples 
were plated in a single well of a 24-well culture plate and assessed for survival and GFP 
expression via flow cytometry after seventy-two hours. The optimal method resulting 
from this analysis of 1200V, 10ms pulse length, and 2 pulses was then used as the 
baseline comparison for evaluation of a method proposed by a publication describing 
Cas9-mediated modification in hiPSCs. This alternate approach employed a lesser cell 
electroporation density of 5*105 cells, varied electroporation settings of 1100V, 30ms 
pulse length, and 1pulse, and the use of a smaller 10μL electroporation cuvette tip. [33] 
For this experiment, the variables modulated included plasmid concentration, tip size 
and electroporation cell density, and the set of three electroporation parameters. Plating 
density was held constant at 1*106 cells per well of a 6-well culture plate and cells were 
assessed via flow cytometry after seventy-two hours. 
Given the optimal electroporation protocol, the remaining variable to potentially 
improve transfection efficiency was plasmid concentration. Various series of testing were 
performed with increasing concentrations of the pCMV-BE3:APOE and pFYF1320 
plasmids and the same low concentration of pEF-GFP. The range of concentrations 
spanned 0.8μg/1*106cells to 4.0μg/1*106cells. As in previous experiments, 
electroporated cells were cultured for seventy-two hours prior to analysis via flow 
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cytometry for survival and GFP expression. The maximum plasmid concentration was 
also repeated at a larger scale in order to assess modification on a bulk scale via Sanger 
sequencing following FACS-enrichment based on GFP expression. 
 Alternate gene delivery approaches were also explored, specifically lipopolymer 
packaging methods. The products TransIT®-LT1 and TransfeX™ were both evaluated as 
transfection reagents. (TransfeX™ Transfection Reagent, ATCC® ACS-4005™) The 
efficacy of TransIT®-LT1 was tested in the iPS-384 cell line. Cells were plated at 
standard passaging density and allowed to expand for forty-eight hours. The transfection 
solution was prepared by incubating 2μg total plasmid with varying ratios of TransIT®-
LT1 ranging from a µL TransIT®-LT1: μg plasmid ratio of 2:1 to 6:1. The established 
ratio of 3:1 for pCMV-BE3:APOE- pFYF1320 was used for the plasmid distribution with 
100ng pEF-GFP. Following the incubation period, the transfection solution was added 
drop-wise to the wells. The cells were immediately returned to the incubator and 
assessed for survival and GFP expression after twenty-four hours. gDNA was also 
harvested at this point for Sanger sequencing of the APOE gene. A larger scale 
transfection was repeated using the TransIT®-LT1. After twenty-four hours, these 
samples were sorted via FACS for GFP expression. The gDNA associated with the 
enriched and depleted populations was submitted for analysis via next-generation 
Illumina sequencing.  
The efficacy of TransfeX was next to be evaluated. For this experiment, iPS-160s 
were plated in a 6-well at standard density and allowed to expand for twenty-four hours. 
The transfection solution was prepared by incubating 4μL TransfeX with 2μg total 
plasmid in serum-free media at room temperature. The established ratio of 3:1 for 
pCMV-BE3:APOE- pFYF1320 was used with 100ng pEF-GFP. Following the incubation 
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period, the transfection solution was added drop-wise to the wells. The iPS-160s were 
immediately returned to the incubator. Microscopy and flow cytometry analysis occurred 
twenty-four hours after transfection.  
3.3. Preparation for clonal line generation 
 In parallel with the efforts to optimize the delivery of the base modification 
system, parameters for the clonal line isolation and characterization were explored. 
Given the emphasis on a homogenous population, it was preferable to minimize the 
number of cells from which the clonal line would be expanded. FACS was chosen as the 
methodology for its ability to isolate single cells. In preparation for sorting modified 
cells, untransfected cells were sorted to predict a survival rate of hiPSCs and provide 
guidance as to the cell numbers required. Untransfected iPS-384 cells were treated with 
5μM RockI for 24 hours, then enzymatically harvested using Accuctase.  Viable cells, 
distinguished by relatively low side scatter and relatively high forward scatter, were 
sorted into 96-well plates containing E8 media and 10μM RockI. 1-, 2-, 10- and 100-
event sorts per well were performed in replicate. Plated cells were cultured for 14 days 
and assessed for cell survival and proliferation via microscopy. 
 In addition to testing of the isolation method, a procedure for assessing off-target 
effects of the base modification system was designed. Five potential off-target sites were 
generated based on the sgRNA sequences for each modification site via CCTop, a 
prediction algorithm published by the Heidelberg Centre for Organismal Studies. [34] 
Appropriate primer pairs were designed for each site. The baseline pre-modification 
sequence for each of the ten sites was determined for the iPS-160 cell line via PCR and 
Sanger sequencing. 
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4. FINDINGS 
4.1. Direct Base Conversion in HEK293 Cells 
The direct base conversion using the model HEK293 cell line verified the 
transfection method, the targeting system for the ApoE ε3 to ApoE ε2 conversion, and 
the colocalization of the plasmids that allows for selection via GFP expression. 
Fluorescent microscopy following transfection of the HEK293 cells clearly indicated 
successful transfection and expression of the GFP cassette. (Figure 1). Survival post-
transfection was also supported by microscopy as cells were seen to expand in culture, 
recovering from the stress inflicted by electroporation. The quantification of these two 
results, survival and GFP expression, indicated a convergence between surviving cells 
and surviving cells that were GFP positive as plasmid concentration increased, 
suggesting both increased cell death and increased transfection efficiency with high 
plasmid concentrations.  (Figure 2). 
 
Figure 1. Microscopy images of HEK293 cells 72hrs post-transfection. Brightfield image 
(left) with the corresponding fluorescent image (right). Electroporation plasmid 
concentration of 1.6μg/1*106cells. 10x magnification. 
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Figure 2. Flow cytometry results characterizing yield of live and GFP-positive HEK293 
cells 72hrs post-transfection. Total yield was normalized to the control sample. Data 
labels indicate the percent of live cells that were found to be GFP-positive for each 
sample. 
 The sequencing results for the varying levels of concentrations did not show a 
significant cytosine to thymine conversion, however, the 1.6μg/1*106 cells plasmid 
concentration sample showed a clear thymine signal at the three bases expected to be 
converted by successful base editing. (Figure 3). This signal indicates that the higher 
plasmid concentration is required to see base conversion in a bulk analysis. When the 
same concentration was repeated followed by enrichment of the GFP positive cells, the 
thymine signal is much more pronounced in the GFP positive population than in the 
unsorted population. No thymine signal above background noise is observed for the GFP 
negative population, all results indicating that there is some colocalization of expression 
of the three plasmids. (Figure 4). 
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Figure 3. Sanger sequencing results for bulk sequencing HEK293 samples at the 158 
amino acid site. Results not shown for electroporation plasmid concentrations 
0.12μg/1*106 cells, 0.2μg/1*106 cells as results are represented by the 0.4μg/1*106 cells 
sample. Black boxes indicate the nucleotide targeted for mutation from cytosine to 
thymine. 
 
Figure 4. Sanger sequencing results for FACS-enriched HEK293 samples at the 158 
amino acid site. Black boxes indicate the nucleotide targeted for mutation from cytosine 
to thymine. 
 The use of next-generation sequencing methods to achieve a quantitative 
measure of this thymine conversion revealed that approximately 14% of the HEK293 
cells were successfully modified from an APOE ε3/ε3 genotype to having at least one 
APOE ε2 allele. Interestingly, the GFP positive population had a lesser incidence of 
indels than the GFP negative population. (Figure 5). 
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Figure 5. Next-generation Illumina sequencing results for FACS-enriched HEK293 
samples indicating genotype based on the sequence at the 158 amino acid site. 
4.2. Generation of hiPSCs 
The generation of hiPSCs required verification of a stable genome over the course of 
reprogramming. Sanger sequencing confirmed that the iPS-160 and the iPS-384 cell 
lines were genotyped as APOE ε4/ε4 before and after the reprogramming occurred. 
(Figure 6). 
 
Figure 6. Genotyping of hiPSC lines via Sanger sequencing. Sequencing was performed 
before and after reprogramming. The red boxes indicate the codons whose 
polymorphisms define the allele present.  
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4.3. Electroporation Optimization in hiPSCs 
Given the lack of success generating viable cells using the exact protocol used to effect 
transfection in the HEK293 cells in addition to a general lack of literature citing 
protocols using the Neon Transfection System to modify hiPSC lines, it was necessary to 
take such an involved approach to determining the optimal electroporation settings. 
Evaluation of different combinations of voltage, pulse length, and number of pulses 
suggested that a combination of 1200V, 10ms or 20ms, and 1 or 2 pulses generated 
consistent results with respect to survival and GFP expression as well as limited 
variability between the different combinations. 1200V, 10ms, and 2 pulses was selected 
as the protocol with the average results for those groups. (Figure 7). 
 
Figure 7. Flow cytometry results from 24-well optimization of the electroporation 
settings used characterizing yield of live and GFP-positive iPS-160 cells 72hrs post-
transfection.  
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 Discovery of literature that did use the Neon Transfection System in pluripotent 
stem cells offered an additional parameter of the electroporation tip size and the 
resulting possible electroporation cell density. Comparison of the previously established 
optimal method and this method did not offer evidence for using the 10µL tip procedure. 
Modification of the electroporation tip from 100μL to 10μL did not improve the viability 
or transfection efficiency of the electroporation method. (Figure 8). 
 
Figure 8. Flow cytometry results characterizing yield of live and GFP-positive iPS-
160 cells 72hrs post-transfection. Total yield was normalized to the maximum value. 
Data labels indicate the percent of live cells that were found to be GFP-positive for 
each sample. 
 Plasmid concentration remained as the final major variable. Achieving 
convergence between survival and GFP expression was desired as this convergence in the 
HEK293 cell verification model corresponded with successful base editing. Such a 
convergence would also increase the chances of any one live cell expressing the genetic 
modification given the evidence supporting coexpression of all three plasmids. 
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Increasing the base editing plasmid concentration never achieved such a convergence, 
suggesting that the optimal maximum plasmid concentration has not yet been tested. 
(Figure 9). This is further supported by the lack of successful cytosine to thymine 
conversion at both conversion sites observed even after FACS-mediated enrichment for 
GFP expression. (Figure 10). The seemingly heterogenous representation of the 112-site 
sequence in both the GFP positive and the GFP negative populations presents an 
immediate complication for evaluating base editing at that site, particularly as the 
earliest passages of these cell lines did not display such heterogeneity. Future work 
assessing the genomic stability of these lines will be required, particularly as the 112-site 
is that to be targeted in achieving the APOE ε4 to APOE ε3 conversion for generating the 
first new clonal lines.  
 
Figure 9. Flow cytometry results from plasmid concentration optimization 
characterizing yield of live and GFP-positive iPS-160 cells 72hrs post-transfection. 
Data labels indicate the percent of live cells that were found to be GFP-positive for 
each sample. 
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Table 2. FACS results from large-scale electroporation of iPS-160 cells 72hrs post-
transfection, including yield and relative GFP expression for both samples.  
 27 
 
 
 28 
 
Figure 10. Sanger sequencing results from the bulk enrichment of the large-scale 
electroporation of iPS-160 cells. Black boxes indicate the nucleotide targeted for 
mutation from cytosine to thymine for each conversion site. 
4.4. Alternate Transfection Methods in hiPSCs 
Use of the TransIT®-LT1 reagent did not result in a greater incidence of GFP 
expression in live cells than that observed in electroporation. (Figure 11). However, the 
sequencing results clearly indicated a conversion signal above background at the 158 site 
for the APOE ε3 to APOE ε2 conversion. This conversion was most clearly observed in 
the sample with a 4:1 ratio of μL TransIT-LT1: μg total plasmid. (Figure 12). The next-
generation sequencing results confirmed and quantified the base conversion for a 
replicate sample, revealing an editing efficiency of 4.19% and indel frequency of 1.35%. 
(Figure 13). Given that this sequencing was performed on a bulk population, it is 
probable that the editing efficiency would be even greater if quantified from an enriched 
population based on positive GFP expression. 
 
Figure 11. Flow cytometry results from transfection reagent ratio optimization for 
TransIT®-LT1 characterizing yield of live and GFP-positive iPS-384 cells 24hrs post-
transfection. Data labels indicate the percent of live cells that were found to be GFP-
positive for each sample. 
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Figure 12. Sanger sequencing results from the transfection reagent ratio optimization for 
TransIT®-LT1.  
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Figure 13. Next-generation Illumina sequencing results for TransIT®-LT samples 
indicating genotype based on the sequence at the 158 amino acid site. The GFP-only 
sample is presented here as a control. 
The alternate transfection reagent Transfex did result in an improved incidence of 
GFP expression in live cells 24-hours post-transfection than that observed via 
electroporation 72-hours post-transfection. Such increased efficiency is readily apparent 
in the microscopy images captured at this point in time. (Figure 14) This suggests that 
use of this reagent may result in an even greater successful base editing efficiency than 
the TransIT®-LT1 reagent. Such prediction is further supported by the flow cytometry 
analysis of the transfected cells in which it was observed that use of the Transfex reagent 
appears to be closer to achieving the previously mentioned convergence between live 
cells and GFP expression. (Figure 15) 
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Figure 14. Microscopy images of iPS-160 cells immediately preceding and 24hrs 
following transfection with Transfex reagent. 10x magnification. 
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Figure 15. Flow cytometry results characterizing yield of live and GFP-positive iPS-160 
cells 24hrs post-transfection. Total yield was normalized to the maximum yield 
observed. Data labels indicate the percent of live cells that were found to be GFP-positive 
for each sample. 
4.5. Preparation for Clonal Line Generation 
The control iPS-384 cells isolated through FACS failed to proliferate after incubating 
over 14 days. Potential avenues for improving future yield include increased cell 
numbers sorted into each well, modulated concentrations of RockI, and the use of mouse 
embryonic fibroblasts to encourage proliferation. Alternate isolation methods could also 
be explored, such as mechanical separation of colonies. 
Sanger sequencing for the ten predicted off-target sites resulted in confirmed 
baseline sequencing for six of the ten sites. Three of the five sites identified for the 112 
off-target analysis did not return sequencing data that matched the expected sequence or 
even the intended chromosome, indicating that the primers used require redesign. One 
of the five sites identified for the 158 off-target analysis simply did not yield sufficient 
product for a confident analysis.  
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Off-
Targ
et 
Site 
Location 
Mismatch
es 
Expected Sequence Actual Sequence 
112-1 
chr4:24913056
-24913078 
2 
GAGG[GGCGCGGCCGCC
] 
Not found 
112-2 
chr11:4638071
1-46380729 
1 GACGAGCGCGGCCGCC GACGAGCGCGGCCGCC 
112-3 
chr16:6715547
8-67155500 
2 
GGCG[AGCGCGGCCGCC
] 
Not found 
112-4 
chr14:1025170
00-102517018 
1 GACG[TCCGCGGCCGCC] Not found 
112-5 
chr1:23743300
-23743318 
2 
GGAG[TGCGCGGCCGCC
] 
GGAGTGCGCGGCCGCC 
158-1 chr11:944367 3 
CCTGcTACAaTGCCAGGC
aCTT 
CCTGCTACAATGCCAGGC
ACTT 
158-2 
chr19:4235633
0 
3 
CCTaGgACACTGCCAGcC
GCTT 
CCTAGGACACTGCCAGCC
GCTT 
158-3 
chr19:4240132
5-42401343 
1 CTCC[TGGCAGTGTACC] CTCCTGGCAGTGTACC 
158-4 
chr1:14898747
1-148987489 
1 CGCA[TGGCAGTGTACC] Not found 
158-5 
chr18:5482361
3-54823631 
2 TACC[TGGCAGTGTACC] TACCTGGCAGTGTACC 
Table 3 Results from Sanger sequence analysis determining baseline sequence of 
potential off-target sites in the iPS-160 cell line. 
5. SUMMARY & DISCUSSION 
The use of the HEK293 cell line provided verification of the delivery method, 
CRISPR/Cas9 system, and targeting sequence with respect to direct base conversion at 
the 158 amino acid site in that cell line. This verification demonstrated the functionality 
of the modified base editor in effecting an ε3 to ε2 conversion at the 158 site as reported 
by Komor et al. (2016). The same electroporation methodology did not effect the base 
conversion in hiPSC lines, however, use of a lipofection technique with comparable 
plasmid concentration did result in confirmed base editing at the 158 site in the iPS-160 
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cell line. Successful base editing at the 112 site was not able to be observed given a 
sequencing artifact at the targeted nucleotide. 
With the promising establishment of the base modification and clonal line 
isolation methods, future work will first and foremost involve the implementation of 
these established methods to generate the isogenic ε3/3 clonal lines from the current 
ε4/4 lines. The prevalence of off-target effects will be assessed for the 112-targeting 
modification system. The methodology would then be repeated to generate the 
corresponding ε2/2 clonal lines with off-target effect assessment performed for the 158-
targeting modification system. Differentiation from pluripotency to neuronal cell types, 
specifically the astrocytes responsible for ApoE production in vivo, would provide 
opportunity for a variety of analyses to assess differences in cell function that could only 
be attributed to the differences in the APOE variant. These potential analyses include 
assays for cholesterol transport levels, extracellular Aβ accumulation, expression of 
phosphorylated tau, and cell survival. Any differences observed would help to clarify the 
role of ApoE and the effects of the isoforms on the pathogenesis of Alzheimer’s disease. 
Such an outcome would be a new model for in vitro study of Alzheimer’s disease and 
could provide the missing human component for drug screening currently thwarted by 
rodent models. Given success of this system to model APOE variants, it is also possible 
that this genetic modification model in hiPSC lines could be applied to other genetic 
targets identified as being correlated with varied risk of developing AD or other diseases.  
 35 
 
REFERENCES 
 
[1]  "2017 Alzheimer’s Disease Facts and Figures," Alzheimer's and Dementia, no. 13, 
pp. 325-373, 2017.  
[2]  "Changing the Trajectory of Alzheimer's Disease," Alzheimer's Association, 2015. 
[3]  "Estimates of Funding for Various Research, Condition, and Disease Categories 
(RCDC)," U.S. Department of Health & Human Services, 10 February 2016. 
[Online]. [Accessed 2017]. 
[4]  "Health, United States, 2015: With Special Feature on Racial and Ethnic Health 
Disparities," National Center for Health Statistics, Hyattsville, MD, 2016. 
[5]  M. M. ,. B. D. S. Eric Karran, "The amyloid cascade hypothesis for Alzheimer's 
disease: an appraisal for the development of therapeutics," Nature Reviews Drug 
Discovery, vol. 10, no. 9, pp. 698-712, September 2011.  
[6]  S. L. C. a. R. Vassar, "The Alzheimer's disease β-secretase enzyme, BACE1," 
Molecular Neurodegeneration, p. 22, 15 November 2007.  
[7]  P. D. X. J. G. Q. Shirwany NA, "The amyloid beta ion channel hypothesis of 
Alzheimer's disease," Neurophysiatric Disease and Treatment, vol. 4, no. 5, pp. 
597-612, October 2007.  
[8]  H. U. W. S. M. J. T. J. B. M. M. M. R. F. D. A. S. L. W. D. K. M. M. U. Hick M, 
"Acute function of secreted amyloid precursor protein fragment APPsα in synaptic 
plasticity," Acta Neuropathologica, vol. 129, no. 1, pp. 21-37, January 2015.  
[9]  J. L. B. P. C. G. L. H. Y. W.-Y. H. M. J. A. A. P. W. R. J. B. C. A. H. K. A. W. N. 
L. E. A. H. C. M. C. a. A. D. R. M. A. Pericak-Vance, "Linkage studies in familial 
Alzheimer disease: Evidence for chromosome 19 linkage," American Journal of 
Human Genetics, vol. 48, no. 6, pp. 1034-1050, June 1991.  
[10]  C. F. a. K. Garai, "Concerning the structure of apoE," Protein Science, 1 Oct 2013.  
[11]  C. A. P.-L. K. H. W. Danny M. Hatters, "Apolipoprotein E structure: insights into 
function," Trends in Biomedical Sciences, vol. 31, no. 8, pp. 445-454, August 2006.  
 36 
 
[12]  A. M. S. W. J. S. B. J. C. C. M. H. S. H. J. M. A. P.-V. D. G. a. A. D. R. D E 
Schmechel, "Increased amyloid beta-peptide deposition in cerebral cortex as a 
consequence of apolipoprotein E genotype in late-onset Alzheimer disease," 
Proceedings of the National Academy of Sciences, vol. 90, no. 20, 15 October 1993.  
[13]  J. M. C. K. G. Y. W. H. J. A. S. G. B. C. F. a. D. M. H. Philip B. Verghese, "ApoE 
influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in 
physiological conditions," Proceedings of the National Academy of Sciences, vol. 
110, no. 19, 25 April 2013.  
[14]  C. K. T. X. H. &. B. G. Liu, "Apolipoprotein E and Alzheimer disease: risk, 
mechanisms and therapy," Nature Reviews Neurology, vol. 9, no. 4, pp. 184-184, 
2013.  
[15]  P. Walter A. Kukull, P. Roger Higdon, M. James D. Bowen and e. al, "Dementia 
and Alzheimer Disease Incidence: A Prospective Cohort Study," Archives of 
Neurology, vol. 59, no. 11, pp. 1737-1746, 2002.  
[16]  R. F. d. B. a. M. A. Ikram, "Cardiovascular risk factors and future risk of 
Alzheimer’s disease," BMC Medicine, vol. 12, 11 November 2014.  
[17]  V. E. L. K. B. D. C. K. N. T. K. M. M. C. Yaffe K, "Posttraumatic Stress Disorder 
and Risk of Dementia Among US Veterans," Archives General Psychiatry, vol. 67, 
no. 6, pp. 608-613, 2010.  
[18]  Y. L. X. L. S. Z. J. Z. X. Z. G. T. Yanjun Li, "Head Injury as a Risk Factor for 
Dementia and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of 32 
Observational Studies," PLoS One, vol. 12, no. 1, 9 January 2017.  
[19]  H. A. B. A. A. G. A. T. A. B. Z. a. Y. W. May A BeydounEmail author, 
"Epidemiologic studies of modifiable factors associated with cognition and 
dementia: systematic review and meta-analysis," BMC Public Health, vol. 14, p. 
643, 24 June 2014.  
[20]  S. P. Valenzuela MJ, "Brain reserve and dementia: a systematic review," 
Psycological Medicine, vol. 36, no. 4, pp. 441-454, April 2006.  
[21]  "Animal Models of Alzheimer Disease," Cold Spring Harbor Perspectives in 
Medicine, November 2012.  
 37 
 
[22]  M. C.-T. a. A. García-Osta, "Current Animal Models of Alzheimer’s Disease: 
Challenges in Translational Research," Frontiers in Neurology, no. 5, p. 182, 24 
September 2014.  
[23]  F. M. L. a. K. N. Green, "Animal Models of Alzheimer's Disease," Cold Spring 
Harbor: Perspectives in Medicine, vol. 2, no. 11, 1 November 2012.  
[24]  R. F. a. A. Cedazo-Minguez, "Successful therapies for Alzheimer’s disease: why so 
many in animal models and none in humans?," Frontiers in Pharmacology, vol. 5, 
p. 146, 25 June 2014.  
[25]  Y. S. Takahashi K, "Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors," Cell, vol. 126, no. 4, pp. 663-76, 25 
August 2006.  
[26]  N. M. a. M. S. Rao, "A Review of the Methods for Human iPSC Derivation," 
Methods in Molecular Biology, vol. 997, pp. 23-33, 2013.  
[27]  M. N. a. M. Otsu, "Development of Sendai Virus Vectors and their Potential 
Applications in Gene Therapy and Regenerative Medicine," Current Gene Therapy, 
vol. 12, no. 5, pp. 410-416, October 2012.  
[28]  S. C. C. W. v. d. B. M. H. C. A. R. C. D. D. S. D. W.-v. O. A. A. W. C. R. B. A. O. 
V. C. F. C. L. M. Richard P. Davis, "Cardiomyocytes Derived From Pluripotent 
Stem Cells Recapitulate Electrophysiological Characteristics of an Overlap 
Syndrome of Cardiac Sodium Channel Disease," Circulation, vol. 125, no. 25, pp. 
3079-3091, 25 June 2012.  
[29]  E. P. P. H. K. S. M. C. M. J. T. C. A. F. Y. M. G. J. M. F. S. A. V. V. T. M. S. &. L. 
S. Gabsang Lee, "Modelling pathogenesis and treatment of familial dysautonomia 
using patient-specific iPSCs," Nature, vol. 461, pp. 402-406, 17 September 2009.  
[30]  C. R. M. H. C. R. P. S. D. G. C. T. S. L. N. P. B. D. M. W. D. J. S. T. L. Young-
Pearse, "The familial Alzheimer's disease APPV717I mutation alters APP 
processing and Tau expression in iPSC-derived neurons," Human Molecular 
Genetics, vol. 23, no. 13, pp. 3523-3536, 12 February 2014.  
[31]  Y. B. K. M. S. P. J. A. Z. &. D. R. L. Alexis C. Komor, "Programmable editing of a 
target base in genomic," Nature, vol. 533, pp. 420-242, 2016.  
 38 
 
[32]  F. Z. Yi-ye Zhou, "Integration-free Methods for Generating Induced Pluripotent 
Stem Cells," Genomics, Proteomics & Bioinformatics, vol. 11, no. 5, pp. 284-287, 
October 2013.  
[33]  B. M. A. G. J. V. S. P. M. H. L. A. G. E. a. E. G. S. Sara E. Howden, "A Cas9 
Variant for Efficient Generation of Indel-Free Knockin or Gene-," Stem Cell 
Reports, vol. 7, no. 3, pp. 508-517, 13 September 2016.  
[34]  T. T. ,. M. d. S. K. J. W. ,. J. L. M. Manuel Stemmer, "CCTop: An Intuitive, 
Flexible and Reliable CRISPR/Cas9 Target Prediction Tool," PLOS One, 24 April 
2015.  
 
 
 
